Peringkat dalam Saham
#25836
Mendus AB (publ), a biopharmaceutical entity formerly known as Immunicum AB... Mendus AB (publ), a biopharmaceutical entity formerly known as Immunicum AB (publ) until its name change in June 2022, specializes in developing immunotherapies and vaccines designed to prevent cancer recurrence. Its primary investigational compound, ilixadencel, is currently progressing through a Phase II MERECA clinical study for kidney cancer, alongside Phase I/II trials targeting liver cancer and gastrointestinal stromal tumors. Additionally, the company is advancing DCP-001, which is undergoing Phase II ADVANCE-II clinical research for acute myeloid leukemia and Phase I/II ALISON trials for ovarian cancers. Mendus maintains research partnerships with PCI Biotech Holding ASA to explore novel cancer vaccination approaches and with the Icahn School of Medicine at Mount Sinai. Founded in 2002, Mendus AB is headquartered in Stockholm, Sweden.
Kapitalisasi Pasar
$45.86M
Perubahan (1 hari)
-0.15%
Perubahan (1 tahun)
-6.28%
Perdagangan Mendus AB (publ) (IMMU)
Harga IMMU dengan kapitalisasi pasar B
Kapitalisasi pasar dari Mendus AB (publ)(IMMU)
Kapitalisasi Pasar: $45.86M
Per August 2026, Mendus AB (publ) memiliki kapitalisasi pasar sebesar $45.86M. Ini menjadikan Mendus AB (publ) sebagai perusahaan 25836th paling bernilai di dunia menurut data kami. Kapitalisasi pasar adalah nilai total saham beredar dari perusahaan publik dan biasanya digunakan untuk mengukur seberapa besar nilai sebuah perusahaan.
Riwayat kapitalisasi pasar Mendus AB (publ) dari 2013 hingga 2026
IMMU dibandingkan dengan 5 teratas stocks paling populer
| Harga IMMU |
|
Aset B |
Pasar B |
Hasil |
|
|
|
|
$5.257T
|
+11,462,312.92%
|
|
|
|
|
$4.599T
|
+10,027,128.07%
|
|
|
|
|
$4.107T
|
+8,954,186.11%
|
|
|
|
|
$3.577T
|
+7,799,997.77%
|
|
|
|
|
$2.807T
|
+6,121,148.29%
|
